St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment

Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.

St. Jude Medical Inc.is working with FDA to design a new U.S. pivotal trial of its EnligHTN multielectrode renal denervation system for patients with drug-resistant high blood pressure after patient-enrollment problems led it to discontinue the sham-controlled EnligHTN IV

trial.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D